VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTGN
Previous Symbol
CUSIPN/A
Phone650-577-3600
Debt
Debt-to-Equity RatioN/A
Current Ratio6.52
Quick Ratio6.52
Price-To-Earnings
Trailing P/E Ratio-1.53
Forward P/E Ratio-1.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.25 million
Price / Sales41.99
Cash FlowN/A
Price / CashN/A
Book Value$0.30 per share
Price / Book5.63
Profitability
EPS (Most Recent Fiscal Year)($1.11)
Net Income$-14,340,000.00
Net MarginsN/A
Return on Equity-305.48%
Return on Assets-174.48%
Miscellaneous
Employees9
Outstanding Shares31,060,000
Market Cap$55.59 million
OptionableNot Optionable
Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions
What is Vistagen Therapeutics' stock symbol?
Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."
How were Vistagen Therapeutics' earnings last quarter?
Vistagen Therapeutics Inc (NASDAQ:VTGN) released its earnings results on Monday, October, 29th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.13. View Vistagen Therapeutics' Earnings History.
When is Vistagen Therapeutics' next earnings date?
What price target have analysts set for VTGN?
4 equities research analysts have issued 1 year price targets for Vistagen Therapeutics' shares. Their forecasts range from $6.00 to $22.00. On average, they expect Vistagen Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 491.7% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics.
What is the consensus analysts' recommendation for Vistagen Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vistagen Therapeutics.
What are Wall Street analysts saying about Vistagen Therapeutics stock?
Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
- 1. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (11/7/2018)
- 2. Maxim Group analysts commented, "VistaGen announced that it has expanded its partnership with Pherin Pharmaceuticals (private) and acquired rights for PH10, a pherin steroid in a nasal spray formulation. Recall that 3-ready pherin steroid for social anxiety disorder, was acquired from Pherin Pharmaceuticals last month." (10/25/2018)
- 3. Chardan Capital analysts commented, "We understand that trial centers are continuing to come online and patient enrollment is on track. Of note, also, is the anticipated data in 2H18 from the NIMH-sponsored 25-patient phase II trial (NCT02484456) of AV-101 as a monotherapy, which will likely provide helpful insight on biomarker and mechanistic data. To support the continued development of AV-101, VistaGen has been issued a patent on the therapeutic uses of AV-101 in MDD (similar to methods of use) as well as a patent on unit dose formulations (almost tantamount to composition of matter). The patents provide protection for AV-101 through 2034." (6/29/2018)
Has Vistagen Therapeutics been receiving favorable news coverage?
Media stories about VTGN stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vistagen Therapeutics earned a daily sentiment score of 0.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Vistagen Therapeutics' key competitors?
Some companies that are related to Vistagen Therapeutics include Ocular Therapeutix (OCUL), ProMetic Life Sciences (PFSCF), MEI Pharma (MEIP), Kamada (KMDA), Xenon Pharmaceuticals (XENE), Protagonist Therapeutics (PTGX), Sienna Biopharmaceuticals (SNNA), Galectin Therapeutics (GALT), OASMIA PHARMACE/ADR (OASM), Corvus Pharmaceuticals (CRVS), Aeglea Bio Therapeutics (AGLE), Calithera Biosciences (CALA), Newron Pharmaceuticals (NWPHF), Intec Pharma (NTEC) and Spring Bank Pharmaceuticals (SBPH).
Who are Vistagen Therapeutics' key executives?
Vistagen Therapeutics' management team includes the folowing people:
- Mr. Shawn K. Singh, CEO & Director (Age 55)
- Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 68)
- Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 65)
- Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 52)
- Dr. Mark A. Smith, Chief Medical Officer (Age 63)
Who are Vistagen Therapeutics' major shareholders?
Vistagen Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (5.39%).
Which major investors are buying Vistagen Therapeutics stock?
VTGN stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD..
How do I buy shares of Vistagen Therapeutics?
Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vistagen Therapeutics' stock price today?
One share of VTGN stock can currently be purchased for approximately $1.69.
How big of a company is Vistagen Therapeutics?
Vistagen Therapeutics has a market capitalization of $55.59 million and generates $1.25 million in revenue each year. The company earns $-14,340,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.
What is Vistagen Therapeutics' official website?
How can I contact Vistagen Therapeutics?
Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]
MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
